Valion Bio reports positive mouse safety data for Entolimod in U.S.-funded study
Valion Bio said the Armed Forces Radiobiology Research Institute found no evidence of treatment-related toxicity after a single dose of its lead candidate, Entolimod, in a 14-day mouse study. The company said the result supports moving toward a planned therapeutic study on survival and gastrointestinal recovery after radiation exposure, which it expects to be fully funded.
Key points
- Study of 20 male C57BL/6 mice evaluated a single subcutaneous Entolimod dose at 0.72 mg/kg against a saline control, with a 14-day observation period
- Body weight showed no statistically significant overall difference from control (p = 0.1424); blood counts stayed within normal reference ranges; serum chemistry showed normal organ and metabolic function
- Next step is an AFRRI therapeutic study testing whether Entolimod given after radiation exposure improves survival and GI tissue recovery; no start date was given
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.